Login to Your Account


LONDON – The biosimilar version of infliximab has overtaken the originator product Remicade in the U.K., but in spite of lower prices, patient access to the anti-TNF-alpha antibody has not increased, according to the British Biosimilars Association (BBA).

DUBLIN – Even if much of the focus of the inaugural Biopharma Ambition meeting here was on how Ireland can compete to win more investment from the global biopharma industry, scheduling Sir Andrew Dillon, CEO of NICE, suggested a certain amount of realism on the part of the conference organizers.

DUBLIN – The FDA's surprise rejection of Amgen Inc.'s application for approval of Parsabiv (etelcalcetide) in secondary hyperparathyroidism is now looking even more curious, as the same drug is set to gain approval in Europe.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: